{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T21:11:56Z","timestamp":1774991516422,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T00:00:00Z","timestamp":1774915200000},"content-version":"vor","delay-in-days":10,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Novel therapeutic targets are urgently needed for the aggressive malignancy gallbladder cancer (GBC). G-protein regulated inducer of neurite outgrowth 1 (GPRIN1) is a candidate oncogene, but its function in GBC and its connection to mitochondrial dysregulation remain unknown. In this study, we analyzed clinical samples and demonstrated that GPRIN1 is significantly upregulated in GBC tissues, where its high expression correlates with advanced clinical stage and poor patient prognosis. Functional assays revealed that GPRIN1 is essential for GBC progression, driving cell cycle advancement and maintaining mitochondrial homeostasis. By integrating proteomic and molecular analyses, our study delineates a bimodal and hierarchical regulatory program commanded by GPRIN1 to ensure the robust activation of CDK1. In the nucleus, GPRIN1 functions as a transcriptional co-activator, scaffolding and stabilizing E2F1 to drive CDK1 expression. In parallel, it functions at a post-translational level to directly promote CDK1 activation by physically steering the kinase away from its inhibitor, MYT1, and toward its activator, Cdc25C. This dual-pronged regulation culminates in hyperactivated CDK1, which in turn unleashes a PI3K-Akt signaling cascade to couple relentless cell proliferation with the necessary mitochondrial support. Importantly, genetic or pharmacological disruption of this GPRIN1-CDK1-PI3K\/Akt axis completely abrogated tumorigenesis in vitro and in vivo. Taken together, these results reveal GPRIN1 as a master regulator whose dual transcriptional and post-translational control of CDK1 integrates cell cycle progression with mitochondrial homeostasis, suggesting that targeting GPRIN1 may represent a highly specific therapeutic strategy in this lethal malignancy.<\/jats:p>","DOI":"10.1038\/s41419-026-08550-2","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:47:41Z","timestamp":1774057661000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oncogenic GPRIN1 sustains proliferation and mitochondrial homeostasis via dual\u2011layer CDK1-PI3K\/Akt signalling in gallbladder cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Chang","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zijun","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaojian","family":"Ni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingxi","family":"Nan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Houbao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6462-5670","authenticated-orcid":false,"given":"Xuanming","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4026-0440","authenticated-orcid":false,"given":"Min","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"8550_CR1","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet. 2021;397:428\u201344.","journal-title":"Lancet"},{"key":"8550_CR2","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41572-022-00398-y","volume":"8","author":"JC Roa","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Prim. 2022;8:69.","journal-title":"Nat Rev Dis Prim"},{"key":"8550_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00327-y","volume":"6","author":"TJJ de Bitter","year":"2022","unstructured":"de Bitter TJJ, de Reuver PR, de Savornin Lohman EAJ, Kroeze LI, Vink-B\u00f6rger ME, van Vliet S, et al. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ Precis Oncol. 2022;6:83.","journal-title":"NPJ Precis Oncol"},{"key":"8550_CR4","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202406448","volume":"11","author":"S Yan","year":"2024","unstructured":"Yan S, Liu Z, Wang T, Sui Y, Wu X, Shen J, et al. Super-enhancer reprograming driven by SOX9 and TCF7L2 represents transcription-targeted therapeutic vulnerability for treating gallbladder cancer. Adv Sci (Weinh). 2024;11:e2406448.","journal-title":"Adv Sci (Weinh)"},{"key":"8550_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1559465","volume":"16","author":"J Ao","year":"2025","unstructured":"Ao J, Hu M, Wang J, Jiang X. Advancing biliary tract malignancy treatment: emerging frontiers in cell-based therapies. Front Immunol. 2025;16:1559465.","journal-title":"Front Immunol"},{"key":"8550_CR6","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1042\/BST20231090","volume":"52","author":"F Ciccarone","year":"2024","unstructured":"Ciccarone F, Ciriolo MR. Reprogrammed mitochondria: a central hub of cancer cell metabolism. Biochem Soc Trans. 2024;52:1305\u201315.","journal-title":"Biochem Soc Trans"},{"key":"8550_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.981464","volume":"10","author":"JS Stoolman","year":"2022","unstructured":"Stoolman JS, Porcelli AM, Mart\u00ednez-Reyes I. Editorial: Mitochondria as a hub in cellular signaling. Front Cell Dev Biol. 2022;10:981464.","journal-title":"Front Cell Dev Biol"},{"key":"8550_CR8","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1007\/s10555-024-10211-9","volume":"43","author":"F Chen","year":"2024","unstructured":"Chen F, Xue Y, Zhang W, Zhou H, Zhou Z, Chen T, et al. The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy. Cancer Metastasis Rev. 2024;43:1419\u201343.","journal-title":"Cancer Metastasis Rev"},{"key":"8550_CR9","doi-asserted-by":"publisher","first-page":"897","DOI":"10.7150\/ijbs.81609","volume":"19","author":"Y Liu","year":"2023","unstructured":"Liu Y, Sun Y, Guo Y, Shi X, Chen X, Feng W, et al. An overview: the diversified role of mitochondria in cancer metabolism. Int J Biol Sci. 2023;19:897\u2013915.","journal-title":"Int J Biol Sci"},{"key":"8550_CR10","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.3390\/biom14101304","volume":"14","author":"T Arif","year":"2024","unstructured":"Arif T, Shteinfer-Kuzmine A, Shoshan-Barmatz V. Decoding Cancer through Silencing the Mitochondrial Gatekeeper VDAC1. Biomolecules. 2024;14:1304.","journal-title":"Biomolecules"},{"key":"8550_CR11","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41388-021-02105-9","volume":"41","author":"X Hao","year":"2022","unstructured":"Hao X, Bu W, Lv G, Xu L, Hou D, Wang J, et al. Disrupted mitochondrial homeostasis coupled with mitotic arrest generates antineoplastic oxidative stress. Oncogene. 2022;41:427\u201343.","journal-title":"Oncogene"},{"key":"8550_CR12","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1007\/s00018-021-03775-0","volume":"78","author":"A Roca-Portoles","year":"2021","unstructured":"Roca-Portoles A, Tait SWG. Mitochondrial quality control: from molecule to organelle. Cell Mol Life Sci. 2021;78:3853\u201366.","journal-title":"Cell Mol Life Sci"},{"key":"8550_CR13","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1080\/1061186X.2020.1867992","volume":"29","author":"YH Qiu","year":"2021","unstructured":"Qiu YH, Zhang TS, Wang XW, Wang MY, Zhao WX, Zhou HM, et al. Mitochondria autophagy: a potential target for cancer therapy. J Drug Target. 2021;29:576\u201391.","journal-title":"J Drug Target"},{"key":"8550_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2024.119752","volume":"1871","author":"K Deepak","year":"2024","unstructured":"Deepak K, Roy PK, Das CK, Mukherjee B, Mandal M. Mitophagy at the crossroads of cancer development: Exploring the role of mitophagy in tumor progression and therapy resistance. Biochim Biophys Acta Mol Cell Res. 2024;1871:119752.","journal-title":"Biochim Biophys Acta Mol Cell Res"},{"key":"8550_CR15","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1158\/2159-8290.CD-22-0601","volume":"13","author":"C Glytsou","year":"2023","unstructured":"Glytsou C, Chen X, Zacharioudakis E, Al-Santli W, Zhou H, Nadorp B, et al. Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia. Cancer Discov. 2023;13:1656\u201377.","journal-title":"Cancer Discov"},{"key":"8550_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.tcb.2023.03.009","volume":"33","author":"XX Zheng","year":"2023","unstructured":"Zheng XX, Chen JJ, Sun YB, Chen TQ, Wang J, Yu SC. Mitochondria in cancer stem cells: Achilles heel or hard armor. Trends Cell Biol. 2023;33:708\u201327.","journal-title":"Trends Cell Biol"},{"key":"8550_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-022-03641-y","volume":"20","author":"L Ren","year":"2022","unstructured":"Ren L, Yang Y, Li W, Zheng X, Liu J, Li S, et al. CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial-mesenchymal transition, G2\/M phase transition, and PANoptosis. J Transl Med. 2022;20:444.","journal-title":"J Transl Med"},{"key":"8550_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcancer.2021.06.019","volume":"85","author":"L Yu","year":"2022","unstructured":"Yu L, Wei J, Liu P. Attacking the PI3K\/Akt\/mTOR signaling pathway for targeted therapeutic treatment in human cancer. Semin Cancer Biol. 2022;85:69\u201394.","journal-title":"Semin Cancer Biol"},{"key":"8550_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2019.12.008","volume":"80","author":"D Tewari","year":"2022","unstructured":"Tewari D, Patni P, Bishayee A, Sah AN, Bishayee A. Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: a novel therapeutic strategy. Semin Cancer Biol. 2022;80:1\u201317.","journal-title":"Semin Cancer Biol"},{"key":"8550_CR20","doi-asserted-by":"publisher","first-page":"6390","DOI":"10.1021\/acs.jmedchem.1c02064","volume":"65","author":"Z Shi","year":"2022","unstructured":"Shi Z, Tian L, Qiang T, Li J, Xing Y, Ren X, et al. From structure modification to drug launch: a systematic review of the ongoing development of cyclin-dependent kinase inhibitors for multiple cancer therapy. J Med Chem. 2022;65:6390\u2013418.","journal-title":"J Med Chem"},{"key":"8550_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/jnc.12641","volume":"129","author":"JC Nordman","year":"2014","unstructured":"Nordman JC, Phillips WS, Kodama N, Clark SG, Del Negro CA, Kabbani N. Axon targeting of the alpha 7 nicotinic receptor in developing hippocampal neurons by Gprin1 regulates growth. J Neurochem. 2014;129:649\u201362.","journal-title":"J Neurochem"},{"key":"8550_CR22","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s12282-023-01438-5","volume":"30","author":"F Jiang","year":"2023","unstructured":"Jiang F, Yang L, Jiao X. Dynamic network biomarker to determine the critical point of breast cancer stage progression. Breast Cancer. 2023;30:453\u201365.","journal-title":"Breast Cancer"},{"key":"8550_CR23","doi-asserted-by":"publisher","first-page":"9070","DOI":"10.1080\/21655979.2022.2053803","volume":"13","author":"X Cui","year":"2022","unstructured":"Cui X, Zhang B, Li B, Li X. Circular RNA circ_0002360 regulates the Taxol resistance and malignant behaviors of Taxol-resistant non-small cell lung cancer cells by microRNA-585-3p-dependent modulation of G protein regulated inducer of neurite outgrowth 1. Bioengineered. 2022;13:9070\u201385.","journal-title":"Bioengineered"},{"key":"8550_CR24","doi-asserted-by":"crossref","unstructured":"Li M, Shen F, Ni X, Gong Z, Song L, Suo T, et al. GPRIN1 promotes gallbladder cancer progression through the CDK1 pathway. Research Square [Preprint].2022.","DOI":"10.21203\/rs.3.rs-1782796\/v1"},{"key":"8550_CR25","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/hmg\/ddu475","volume":"24","author":"K Tagawa","year":"2015","unstructured":"Tagawa K, Homma H, Saito A, Fujita K, Chen X, Imoto S, et al. Comprehensive phosphoproteome analysis unravels the core signaling network that initiates the earliest synapse pathology in preclinical Alzheimer\u2019s disease brain. Hum Mol Genet. 2015;24:540\u201358.","journal-title":"Hum Mol Genet"},{"key":"8550_CR26","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/19585969.2025.2502028","volume":"27","author":"A Chagraoui","year":"2025","unstructured":"Chagraoui A, Thibaut F, De Deurwaerd\u00e8re P. 5-HT6 receptors: contemporary views on their neurobiological and pharmacological relevance in neuropsychiatric disorders. Dialog Clin Neurosci. 2025;27:112\u201328.","journal-title":"Dialog Clin Neurosci"},{"key":"8550_CR27","doi-asserted-by":"publisher","first-page":"D261","DOI":"10.1093\/nar\/gkr1122","volume":"40","author":"PV Hornbeck","year":"2012","unstructured":"Hornbeck PV, Kornhauser JM, Tkachev S, Zhang B, Skrzypek E, Murray B, et al. PhosphoSitePlus: a comprehensive resource for investigating the structure and function of experimentally determined post-translational modifications in man and mouse. Nucleic Acids Res. 2012;40:D261\u201370.","journal-title":"Nucleic Acids Res"},{"key":"8550_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102943","volume":"59","author":"S Missiroli","year":"2020","unstructured":"Missiroli S, Perrone M, Genovese I, Pinton P, Giorgi C. Cancer metabolism and mitochondria: finding novel mechanisms to fight tumours. EBioMedicine. 2020;59:102943.","journal-title":"EBioMedicine"},{"key":"8550_CR29","doi-asserted-by":"publisher","first-page":"a041534.","DOI":"10.1101\/cshperspect.a041534","volume":"14","author":"TC Kenny","year":"2024","unstructured":"Kenny TC, Birsoy K. Mitochondria and cancer. Cold Spring Harb Perspect Med. 2024;14:a041534.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"8550_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7:16878.","journal-title":"Sci Rep"},{"key":"8550_CR31","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1038\/s41556-024-01513-9","volume":"26","author":"DP Narendra","year":"2024","unstructured":"Narendra DP, Youle RJ. The role of PINK1-Parkin in mitochondrial quality control. Nat Cell Biol. 2024;26:1639\u201351.","journal-title":"Nat Cell Biol"},{"key":"8550_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1270542","volume":"11","author":"S Sokhi","year":"2023","unstructured":"Sokhi S, Lewis CW, Bukhari AB, Hadfield J, Xiao EJ, Fung J, et al. Myt1 overexpression mediates resistance to cell cycle and DNA damage checkpoint kinase inhibitors. Front Cell Dev Biol. 2023;11:1270542.","journal-title":"Front Cell Dev Biol"},{"key":"8550_CR33","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/s41416-023-02468-8","volume":"129","author":"G Massacci","year":"2023","unstructured":"Massacci G, Perfetto L, Sacco F. The Cyclin-dependent kinase 1: more than a cell cycle regulator. Br J Cancer. 2023;129:1707\u201316.","journal-title":"Br J Cancer"},{"key":"8550_CR34","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.devcel.2014.03.012","volume":"29","author":"Z Wang","year":"2014","unstructured":"Wang Z, Fan M, Candas D, Zhang TQ, Qin L, Eldridge A, et al. Cyclin B1\/Cdk1 coordinates mitochondrial respiration for cell-cycle G2\/M progression. Dev Cell. 2014;29:217\u201332.","journal-title":"Dev Cell"},{"key":"8550_CR35","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1158\/1535-7163.MCT-15-0017","volume":"14","author":"R Liu","year":"2015","unstructured":"Liu R, Fan M, Candas D, Qin L, Zhang X, Eldridge A, et al. CDK1-mediated SIRT3 activation enhances mitochondrial function and tumor radioresistance. Mol Cancer Ther. 2015;14:2090\u2013102.","journal-title":"Mol Cancer Ther"},{"key":"8550_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00418-2","volume":"11","author":"Z Shao","year":"2022","unstructured":"Shao Z, Li C, Wu Q, Zhang X, Dai Y, Li S, et al. ZNF655 accelerates progression of pancreatic cancer by promoting the binding of E2F1 and CDK1. Oncogenesis. 2022;11:44.","journal-title":"Oncogenesis"},{"key":"8550_CR37","doi-asserted-by":"publisher","first-page":"106234","DOI":"10.1016\/j.ijsu.2022.106234","volume":"98","author":"CF Feo","year":"2022","unstructured":"Feo CF, Ginesu GC, Fancellu A, Perra T, Ninniri C, Deiana G, et al. Current management of incidental gallbladder cancer: a review. Int J Surg. 2022;98:106234.","journal-title":"Int J Surg"},{"key":"8550_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1183619","volume":"14","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Yuan K, Yang Y, Ji Z, Zhou D, Ouyang J, et al. Gallbladder cancer: current and future treatment options. Front Pharm. 2023;14:1183619.","journal-title":"Front Pharm"},{"key":"8550_CR39","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molcel.2016.02.011","volume":"61","author":"WX Zong","year":"2016","unstructured":"Zong WX, Rabinowitz JD, White E. Mitochondria and cancer. Mol Cell. 2016;61:667\u201376.","journal-title":"Mol Cell"},{"key":"8550_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12929-023-00956-w","volume":"30","author":"SF Wang","year":"2023","unstructured":"Wang SF, Tseng LM, Lee HC. Role of mitochondrial alterations in human cancer progression and cancer immunity. J Biomed Sci. 2023;30:61.","journal-title":"J Biomed Sci"},{"key":"8550_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00407-7","volume":"7","author":"Q Wang","year":"2023","unstructured":"Wang Q, Bode AM, Zhang T. Targeting CDK1 in cancer: mechanisms and implications. NPJ Precis Oncol. 2023;7:58.","journal-title":"NPJ Precis Oncol"},{"key":"8550_CR42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41392-024-02080-z","volume":"10","author":"I Pellarin","year":"2025","unstructured":"Pellarin I, Dall\u2019Acqua A, Favero A, Segatto I, Rossi V, Crestan N, et al. Cyclin-dependent protein kinases and cell cycle regulation in biology and disease. Signal Transduct Target Ther. 2025;10:11.","journal-title":"Signal Transduct Target Ther"},{"key":"8550_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2024.117147","volume":"178","author":"M Sun","year":"2024","unstructured":"Sun M, Ji Y, Zhang G, Li Y, Dong F, Wu T. Posttranslational modifications of E2F family members in the physiological state and in cancer: roles, mechanisms and therapeutic targets. Biomed Pharmacother. 2024;178:117147.","journal-title":"Biomed Pharmacother"},{"key":"8550_CR44","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.tibs.2022.06.007","volume":"47","author":"M Fischer","year":"2022","unstructured":"Fischer M, Schade AE, Branigan TB, M\u00fcller GA, DeCaprio JA. Coordinating gene expression during the cell cycle. Trends Biochem Sci. 2022;47:1009\u201322.","journal-title":"Trends Biochem Sci"},{"key":"8550_CR45","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41392-023-01503-7","volume":"8","author":"S Wang","year":"2023","unstructured":"Wang S, Long H, Hou L, Feng B, Ma Z, Wu Y, et al. The mitophagy pathway and its implications in human diseases. Signal Transduct Target Ther. 2023;8:304.","journal-title":"Signal Transduct Target Ther"},{"key":"8550_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1431968","volume":"12","author":"Y Dong","year":"2024","unstructured":"Dong Y, Zhang X. Targeting cellular mitophagy as a strategy for human cancers. Front Cell Dev Biol. 2024;12:1431968.","journal-title":"Front Cell Dev Biol"},{"key":"8550_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-021-02065-w","volume":"21","author":"Y Guan","year":"2021","unstructured":"Guan Y, Wang Y, Li B, Shen K, Li Q, Ni Y, et al. Mitophagy in carcinogenesis, drug resistance and anticancer therapeutics. Cancer Cell Int. 2021;21:350.","journal-title":"Cancer Cell Int"},{"key":"8550_CR48","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.semcancer.2019.07.015","volume":"66","author":"DP Panigrahi","year":"2020","unstructured":"Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Patra S, Behera BP, et al. The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics. Semin Cancer Biol. 2020;66:45\u201358.","journal-title":"Semin Cancer Biol"},{"key":"8550_CR49","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3892\/mmr.2021.12252","volume":"24","author":"L Wang","year":"2021","unstructured":"Wang L, Yang M, Jin H. PI3K\/AKT phosphorylation activates ERR\u03b1 by upregulating PGC-1\u03b1 and PGC-1\u03b2 in gallbladder cancer. Mol Med Rep. 2021;24:613.","journal-title":"Mol Med Rep"},{"key":"8550_CR50","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.bbcan.2019.03.003","volume":"1871","author":"MC De Santis","year":"2019","unstructured":"De Santis MC, Gulluni F, Campa CC, Martini M, Hirsch E. Targeting PI3K signaling in cancer: challenges and advances. Biochim Biophys Acta Rev Cancer. 2019;1871:361\u20136.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"8550_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114704","volume":"243","author":"L Akl","year":"2022","unstructured":"Akl L, Abd El-Hafeez AA, Ibrahim TM, Salem R, Marzouk HMM, El-Domany RA, et al. Identification of novel piperazine-tethered phthalazines as selective CDK1 inhibitors endowed with in vitro anticancer activity toward the pancreatic cancer. Eur J Med Chem. 2022;243:114704.","journal-title":"Eur J Med Chem"},{"key":"8550_CR52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s43556-023-00165-9","volume":"5","author":"S Qu","year":"2024","unstructured":"Qu S, Xu R, Yi G, Li Z, Zhang H, Qi S, et al. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine. Mol Biomed. 2024;5:6.","journal-title":"Mol Biomed"},{"key":"8550_CR53","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.cell.2019.11.036","volume":"180","author":"F Jacob","year":"2020","unstructured":"Jacob F, Salinas RD, Zhang DY, Nguyen PTT, Schnoll JG, Wong SZH, et al. A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity. Cell. 2020;180:188\u2013204.e22.","journal-title":"Cell"},{"key":"8550_CR54","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.716339","volume":"11","author":"R Zhang","year":"2021","unstructured":"Zhang R, Guo T, Ji L, Yin Y, Feng S, Lu W, et al. Development and application of patient-derived cancer organoidsin clinical management of gastrointestinal cancer: a state-of-the-art review. Front Oncol. 2021;11:716339.","journal-title":"Front Oncol"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08550-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08550-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:02:30Z","timestamp":1774987350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08550-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8550"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08550-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All animal experiments were approved by the Institutional Animal Care and Use Committee of Zhongshan Hospital and conducted in accordance with institutional guidelines. Human tissue sample collection and use were approved by the Clinical Research Ethics Committee of Zhongshan Hospital, and written informed consent was obtained from all patients, as detailed in the Materials and Methods section.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have read and approved the final manuscript and consent to its publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"333"}}